Description
BOTOX 200 Allergan Units is a prescription-only medicine containing botulinum toxin type A, supplied as a white powder for solution for injection. Each vial contains 200 Allergan Units of botulinum toxin type A derived from Clostridium botulinum. The active neurotoxin acts at peripheral cholinergic nerve terminals by inhibiting acetylcholine release at the neuromuscular junction. This temporarily reduces neuromuscular transmission and produces a reversible reduction in targeted muscle activity.
The UK-authorised BOTOX formulation has multiple therapeutic indications. In aesthetic medicine, it is authorised for the temporary improvement in the appearance of moderate to severe glabellar lines, lateral canthal lines (crow’s feet), forehead lines.
BOTOX should only be administered by an appropriately qualified healthcare practitioner with expertise in the relevant indication and the required equipment.
Treatment Areas / Indications
For aesthetic use, the current UK SmPC identifies:
- Glabellar lines between the eyebrows at maximum frown.
- Lateral canthal lines (crow’s feet) at maximum smile.
- Forehead lines at maximum eyebrow elevation.
- Platysma prominence at maximum contraction.
- These aesthetic indications apply to adults where the severity has an important psychological impact.
Administration Parameters
- Professional administration: BOTOX should only be administered by an appropriately qualified healthcare practitioner with expertise in the relevant indication and required equipment, in accordance with national guidelines.
- Treatment frequency: The aesthetic indications should not be treated more frequently than every 3 months.
- Single use: BOTOX is intended for treatment of one patient during a single session, with unused product discarded according to the product information.
Ingredient List
- Active ingredient: Botulinum toxin type A — 200 Allergan Units per vial.
BOTOX 200 Allergan Units is supplied as a powder for solution for injection and requires reconstitution before administration.
Presentation & Longevity
BOTOX 200 Allergan Units is supplied in a clear glass vial containing 200 Allergan Units of botulinum toxin type A. The standard pack comprises one 200-unit vial and package leaflet; packs containing multiple cartons may also be authorised, although not all pack sizes may be marketed.
The unopened product has a 3-year shelf life. The UK SmPC specifies storage in a refrigerator at 2–8°C.
For aesthetic treatment, the documented duration varies by indication. Glabellar-line improvement has been demonstrated for up to 4 months, while crow’s feet and forehead-line studies report effects lasting approximately 4 months on average, with some clinical data showing reduction in line severity for longer periods in selected studies.
Safety Notes / Contraindications
BOTOX is contraindicated in patients with:
- Known hypersensitivity to botulinum toxin type A or any listed excipient.
- Infection at the proposed injection site.
Important precautions include the potential for distant spread of toxin effect, which can result in excessive muscle weakness and serious swallowing, speech or respiratory difficulties.
For aesthetic indications, BOTOX is not recommended for individuals under 18 years. The product is also not recommended during pregnancy, and use during breastfeeding cannot be recommended because sufficient information is unavailable.
The MHRA has issued updated warnings concerning rare cases of iatrogenic botulism following therapeutic or cosmetic use of botulinum toxin products. The MHRA also highlights the risks associated with unlicensed and counterfeit botulinum toxin products.
Regulatory Status
BOTOX 200 Allergan Units is a UK-authorised Prescription-Only Medicine (POM). It is not a dermal filler and is not classified as a CE/UKCA medical device.
The current UK SmPC lists AbbVie Ltd as the marketing authorisation holder and gives UK marketing authorisation PL 41042/0058.
The manufacturer name for the specific manufacturing site is not provided in the current public UK SmPC; therefore, the product page should not infer a manufacturing entity from third-party retail listings.
BOTOX potency is expressed in Allergan units, which are product-specific and not interchangeable with units used for other botulinum toxin preparations.
FAQ
1. What is BOTOX 200 Allergan Units?
BOTOX 200 Allergan Units is a prescription-only medicine containing 200 Allergan Units of botulinum toxin type A in a single vial. The neurotoxin temporarily inhibits acetylcholine release at peripheral cholinergic nerve terminals, reducing neuromuscular transmission and targeted muscle activity. In the UK, BOTOX has several authorised indications spanning aesthetic, neurological, bladder and dermatological conditions. The product should only be administered by an appropriately qualified healthcare practitioner with relevant expertise in the indication being treated.
2. What is BOTOX 200 units used for?
The UK-authorised aesthetic indications include temporary improvement in moderate to severe glabellar lines, lateral canthal lines, forehead lines and platysma prominence in adults where severity has an important psychological impact. The same 200-unit presentation is also authorised for medical indications, including certain forms of focal spasticity, chronic migraine, bladder disorders and severe primary axillary hyperhidrosis. The authorised dose, injection pattern and treatment interval vary substantially according to the indication.
3. Is BOTOX 200 Allergan Units equivalent to 200 units of Bocouture or Azzalure?
No. BOTOX uses Allergan Units, while Bocouture and Azzalure use their own product-specific potency units. Although all three contain botulinum toxin type A, their formulations, potency assays, authorised indications and dosing instructions differ. The BOTOX UK SmPC explicitly states that its units are not interchangeable with other botulinum toxin preparations. Therefore, a 200-Allergan-Unit BOTOX vial should not be treated as equivalent to 200 units of another botulinum toxin product.
